Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q1 2022 · 10-Q
Revenue$388.99K$388.99K+103.4% vs Q1 2021 Net Income-$1.59M-$1.59MN/M vs Q1 2021 EPS Diluted-$0.12-$0.12N/M vs Q1 2021 Operating Income-$1,619,715N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Margins · derivedOperating margin-416.4%+299.6 pt vs Q1 2021
Net margin-409.7%+294.2 pt vs Q1 2021
ended Mar 31, 2022 · filed May 12, 2022 · 42 d after period end